Digest Network Come funziona
Network
/
Società
Cl
Non verificato

Clasp Therapeutics

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaIndustriaOncologia

3 comunicati stampa

Guarda tutti i comunicati
28/04/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial With a First-in-Class T-Cell Engager Designed to Target Cancer Cells With Absolute Specificity
Fonte
Clasp Therapeutics
Emittente
Business Wire
1.00
0
07/11/2024
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting
Fonte
Clasp Therapeutics
Emittente
Business Wire
1.00
0
04/10/2024
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Clasp Therapeutics to Present Preclinical Data Evaluating Novel T Cell Engager Targeting p53 Mutant Solid Tumors
Fonte
Clasp Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0